What is Epitopea?
Founded in 2021, Epitopea operates at the intersection of advanced immunology and oncology. The company specializes in the identification and development of novel cancer antigens, leveraging cutting-edge computational biology to create targeted therapies. By focusing on the underlying mechanisms of tumor recognition, Epitopea aims to deliver highly specific treatments that minimize off-target effects, positioning itself as a high-growth entity within the broader life sciences market. Its strategic location in Cambridge provides proximity to world-class research institutions, facilitating a rapid translation of scientific discovery into clinical applications.
How much funding has Epitopea raised?
Epitopea has raised a total of $31.6M across 2 funding rounds:
Other Financing Round
$650K
Other Financing Round
$31M
Other Financing Round (2022): $650K with participation from Defi Research Institute, Matters, and Smart-Chain
Other Financing Round (2024): $31M led by Advent Life Sciences, Cambridge Innovation Capital, and Investissement Quebec
Key Investors in Epitopea
Advent Life Sciences
A trans-Atlantic venture capital firm specializing in early and mid-stage investments in life sciences, focusing on first-in-class medicines and medical products.
Cambridge Innovation Capital
A premier venture investor with deep ties to the University of Cambridge, supporting high-growth start-ups in the life sciences and deep tech sectors.
Investissement Quebec
A government-backed financial institution dedicated to fostering economic development through strategic equity investments, loans, and financial solutions.
What's next for Epitopea?
With the recent influx of capital, Epitopea is expected to prioritize the advancement of its lead candidates through critical clinical trial phases. The strategic focus will likely shift toward scaling manufacturing capabilities and strengthening intellectual property portfolios to maintain a competitive edge in the immunotherapy space. Furthermore, the involvement of high-profile institutional backers suggests a long-term commitment to building a sustainable, high-impact enterprise capable of delivering transformative medical solutions. Future milestones will likely center on data readouts from ongoing studies and potential partnerships with larger pharmaceutical entities to facilitate global commercialization efforts.
See full Epitopea company page
